Samsung Biologics brings cell line services in-house

Samsung Biologics said Monday it has launched in-house master cell bank production and vector construction services, strengthening its contract development organization capabilities and accelerating drug development timelines. The company introduced the services at a webinar held March 19, titled “Accelerating Vector Construction-to-IND: Achieving a 9-Month Timeline Through Integrated Cell Line Development.” By internalizing processes previously outsourced to external partners, Samsung Biologics

By The Korea Herald